NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
37
MREO Quote, Financials, Valuation and Earnings
Last price:
$3.38
Seasonality move
:
18.25%
Day range:
$3.11 - $3.39
52-week range:
$2.03 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.14x
Volume:
1.8M
Avg. volume:
989.6K
1-year change:
67.84%
Market cap:
$518.2M
Revenue:
$10M
EPS (TTM):
-$0.30
Analysts' Opinion
-
Consensus RatingMereo BioPharma Group PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Mereo BioPharma Group PLC has an estimated upside of 114.45% from its current price of $3.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.34.
Fair Value
-
According to the consensus of 0 analysts, Mereo BioPharma Group PLC has 114.45% upside to fair value with a price target of -- per share.
MREO vs. S&P 500
-
Over the past 5 trading days, Mereo BioPharma Group PLC has underperformed the S&P 500 by -8.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mereo BioPharma Group PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mereo BioPharma Group PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mereo BioPharma Group PLC reported revenues of --.
Earnings Growth
-
Mereo BioPharma Group PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mereo BioPharma Group PLC reported earnings per share of -$0.10.
Enterprise value:
443.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.3M
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | $1.3M | $235K | -- | |
| Operating Income | -- | -- | -$38.1M | -$9M | -$9.1M | |
| EBITDA | -- | -- | -$43.4M | -$5.5M | -$14.4M | |
| Diluted EPS | -- | -- | -$0.30 | -$0.05 | -$0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $86.7M | |
| Total Assets | -- | -- | -- | -- | $88.7M | |
| Current Liabilities | -- | -- | -- | -- | $14.2M | |
| Total Liabilities | -- | -- | -- | -- | $16.2M | |
| Total Equity | -- | -- | -- | -- | $72.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$30.2M | $2.7M | -$7.5M | |
| Cash From Investing | -- | -- | -$699K | -- | -- | |
| Cash From Financing | -- | -- | -- | $7.9M | -$594K | |
| Free Cash Flow | -- | -- | -$30.9M | $2.7M | -$7.5M | |
MREO
Sector
Market Cap
$518.2M
$43.9M
Price % of 52-Week High
66.53%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
67.84%
-29.11%
Beta (5-Year)
0.935
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.52
200-day SMA
Sell
Level
$3.73
Bollinger Bands (100)
Sell
Level
3.69 - 4.47
Chaikin Money Flow
Sell
Level
-35.4M
20-day SMA
Sell
Level
$3.57
Relative Strength Index (RSI14)
Sell
Level
37.39
ADX Line
Sell
Level
12.07
Williams %R
Neutral
Level
-72.2892
50-day SMA
Sell
Level
$3.91
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
301.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1111)
Sell
CA Score
(Annual)
Level (-1.1536)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.5664)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Stock Forecast FAQ
In the current month, MREO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MREO average analyst price target in the past 3 months is --.
-
Where Will Mereo BioPharma Group PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mereo BioPharma Group PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Mereo BioPharma Group PLC?
Analysts are divided on their view about Mereo BioPharma Group PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mereo BioPharma Group PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Mereo BioPharma Group PLC's Price Target?
The price target for Mereo BioPharma Group PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MREO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mereo BioPharma Group PLC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MREO?
You can purchase shares of Mereo BioPharma Group PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mereo BioPharma Group PLC shares.
-
What Is The Mereo BioPharma Group PLC Share Price Today?
Mereo BioPharma Group PLC was last trading at $3.38 per share. This represents the most recent stock quote for Mereo BioPharma Group PLC. Yesterday, Mereo BioPharma Group PLC closed at $3.34 per share.
-
How To Buy Mereo BioPharma Group PLC Stock Online?
In order to purchase Mereo BioPharma Group PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
